Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $2,828,220.30 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 165,393 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30. Following the transaction, the insider directly owned 766,569 shares of the company’s stock, valued at $13,108,329.90. This represents a 17.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $17.64 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average price is $16.57 and its 200-day moving average price is $17.14. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The stock has a market cap of $56.53 billion, a P/E ratio of 51.89 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. Equities research analysts anticipate that Takeda Pharmaceutical Co. will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership increased its holdings in Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after buying an additional 2,854,069 shares in the last quarter. UBS Group AG lifted its stake in Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after acquiring an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd lifted its stake in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after acquiring an additional 1,426,184 shares during the period. Van ECK Associates Corp boosted its holdings in shares of Takeda Pharmaceutical by 98.4% during the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after acquiring an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 1,070.7% during the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after acquiring an additional 880,289 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TAK has been the subject of several recent analyst reports. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.